The Consortia Model improves and advances research outcomes
The most important conceptual difference between the classical clinical trial and the consortia approach is
that the Consortia Model, with its highly experienced clinical scientists, is involved on an intellectual advisory
level with every step of clinical investigation in a GI cancer study. Classical clinical trials groups "just run
the study" with their only substantive role being patient accrual.
Translational science is motivated by the need to provide effective treatments to the right patients at the
right doses for a specific disease indication. The term, as used in the health sciences, refers to real-time translation
of bench science conducted only in a lab, to bedside clinical practice with eventual dissemination to population-based
community interventions. (Source: NIH)
The discipline of clinical and translational science encompasses a broad spectrum of research, extending from basic
discoveries with implications for human health to community-based epidemiologic and health services studies.
The unifying theme is a commitment to apply scientific methodologies to address a health need.
SCTS (The Society for Clinical and Translational Science) defines it as:
"...a multi-dimensional, cross-cutting discipline that encompasses multidisciplinary investigative teams from
many different subspecialty areas. Moreover, success in clinical and translational science commonly requires constructive
partnerships with industry, granting agencies, public health agencies, and regulatory agencies. "
For more information on how the Consortia Model applies translational science to successful research outcomes, please
contact John S. Macdonald, MD at: firstname.lastname@example.org
|| Clinical Trials Group
|| Consortia Model
|| Developed by Sponsor
||Developed by Sponsor in consultation with Consortia "Brain Trust/Virtual Advisory Board"
||Written by Sponsor
||Written by Consortia with Sponsor
|FDA/Regulatory Agency Contact
||Done by Sponsor
||Consortia functions as "Virtual Advisory Board" to help Sponsor with FDA/Regulatory issues
|Translational science with clinical outcomes
||Little or NONE
||Consortia interfaces translational science with clinical outcomes and can show the
value of translational science
to a positive outcome of regulatory approval process*; consortia institutions have capability to collect tissue and
access to labs to analyze and interpret data; consortia sites were selected for their access to patients with specific
diseases and for their ability to enroll such patients on clinical trials.
|Role of Investigators
||Accrue patients to established protocol
||The consortium investigators are the "Brain Trust“ – clinical scientists who are not only involved in the conceptual
design of trial, but also are actively enrolling patients to a trial. **
|Role of investigators in result analysis/ interpretation
||Consortia puts the whole package (clinical & translational science) together into a
coherent whole which clarifies
the value of this package to the regulatory approval process along with providing comprehensive information to the
sponsor to facilitate go-no go decisions.
*Interfacing clinical & translational science is critical to the Consortia’s contribution to research projects.
**Throughout the clinical trial the Consortia contributes ideas and experience.